Press monitoring
PCI Biotech: Dose escalation in the bile duct cancer study completed with promising early signs of efficacy
22.1.2016 | Press monitoring
Oslo, 22 January 2016 - PCI Biotech (PCIB) reported today that the treatment evaluation of the fourth dose cohort in the Phase I/II study of fimaporfin (Amphinex®) in patients with inoperable bile duct cancer has been completed. The Cohort Review Committee (CRC) of clinical experts and company representatives has recommended that the study...
No sex required: Gene trigger for asexual reproduction discovered
22.1.2016 | Press monitoring
A German-Israeli team led has discovered a gene trigger in the moss Physcomitrella patens which leads to offspring without fertilization. The researchers assume that this mechanism is conserved in evolution and holds the key to answer fundamental questions in biology. "Just like humans and animals, mosses possess egg cells and motile sperm. That...
MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
21.1.2016 | Press monitoring
IRVINE, CA, and HERSTAL, BELGIUM - January 21, 2016 - MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 Frost & Sullivan Global Technology Innovation Award for its commitment to technological innovation to reduce unnecessary prostate biopsies.
oncgnostics GmbH: Safe Diagnostics for Women Tested HPV-Positive
20.1.2016 | Press monitoring
JENA, GERMANY and FRICKENHAUSEN, GERMANY--(Marketwired - Jan 20, 2016) - With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces...
NIST simulates fast, accurate DNA sequencing through graphene nanopore
20.1.2016 | Press monitoring
Researchers at the National Institute of Standards and Technology (NIST) have simulated a new concept for rapid, accurate gene sequencing by pulling a DNA molecule through a tiny, chemically activated hole in graphene - an ultrathin sheet of carbon atoms - and detecting changes in electrical current. The NIST study suggests the method could...
MDxHealth Analytical Validation Study on AssureMDx for Bladder Cancer Published in The Journal of Urology
19.1.2016 | Press monitoring
IRVINE, CA, and HERSTAL, BELGIUM, January 19, 2016 - MDxHealth SA (Euronext: MDXH), today announced that data demonstrating the clinical potential of its urine-based epigenetic bladder cancer test AssureMDx to aid urologists in the management of patients presenting with haematuria (blood in the urine), has been published in The Journal of...
Summit Therapeutics Granted Key European Patent for Novel C. difficile Antibiotic Ridinilazole
19.1.2016 | Press monitoring
Oxford, UK, 19 January 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection ('CDI'), announces that the European Patent Office ('EPO') has granted a key patent covering the novel antibiotic, ridinilazole, and...
Santhera Signs Distribution and Supply Agreement for Raxone® with Ewopharma Covering Eastern Europe and The Baltics
18.1.2016 | Press monitoring
Santhera Pharmaceuticals (SIX: SANN) announces that it has signed an agreement with Ewopharma to launch Raxone ® for the treatment of Leber's hereditary optic neuropathy (LHON) in a number of Eastern European countries (Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia) and the Baltics (Estonia, Latvia and...
Cloaking chemo drugs in cellular bubbles destroys cancer
18.1.2016 | Press monitoring
The chemotherapy drug paclitaxel is commonly used to treat breast, lung and pancreatic cancers, slowing their growth by preventing cancerous cells from replicating. But once administered the drug is attacked by the body's defenses, necessitating larger doses that result in complications such as joint pain, diarrhea and an impaired ability to...
FDA gives OK for company\'s genetically engineered potato
15.1.2016 | Press monitoring
A potato genetically engineered to resist the pathogen that caused the Irish potato famine is as safe as any other potato on the market, the Food and Drug Administration says. In a letter Tuesday to Idaho-based J.R. Simplot Co., the FDA said the potato isn't substantially different in composition or safety from other products already on the...
